The Relation of Hepcidin, Vitamin D and Inflammatory Parameters, and Effects on Intensive Care Unit Outcome in Critically Ill COVID-19 Patients

Year 2022, Volume: 75 Issue: 4, 525 - 529, 20.01.2023

Leyla Ferlicolak , Nur Seren Bildiren Özlem Doğan , Merve Yüksel Meltem Yüksel , Neriman Defne Altıntaş

https://doi.org/10.4274/atfm.galenos.2023.66487

Abstract

Objectives: Aim of this study was to evaluate hepcidin levels and its correlation with inflammatory markers, vitamin D levels as well as its effects on intensive care unit (ICU) mortality in critically ill coronavirus disease-2019 (COVID-19) patients.

Materials and Methods: Adult patients those were admitted to pandemic ICU between March 1st, 2021 and May 17th 2021 were prospectively included to the study. Hepcidin levels and inflammatory markers on day 1, 2, 3 and 7, admission vitamin D levels, length of ICU stay and ICU mortality were recorded and analysed.

Results: Median age of patients was 60.5 (52.50-71.25) and 20 (66.7%) of them was male. It was observed that hepcidin levels and lymphocyte counts were increased significantly from day 1 to day 7 (p=0.01 and p<0.01, respectively). In contrast, C-reactive protein (CRP) and procalsitonin levels were decreased from day 1 to day 7 (p=0.01 and p<0.01, respectively). In the analysis admission hepcidin levels and inflammatory markers [IL-6 (p=0.61), CRP (p=0.82) and ferritin (p=0.27)], vitamin D (p=0.13) and iron level (p=0.90) was not correlated. There was no correlation between hepcidin levels and ICU mortality (p=0.95)

Conclusion: In this study, hepcidin levels were above normal limits in critically ill COVID-19 patients. However, our findings do not support the use of hepcidin, IL6, serum ferritin, and vitamin D levels in predicting COVID-19 mortality.

Keywords

ICU , Hepcidin , Mortality

Ethical Statement

-

Supporting Institution

-

Project Number

-

Thanks

-

Kritik COVID-19 Hastalarında Hepsidin, D Vitamini ve Enflamasyon Belirteçlerinin İlişkisi ve Yoğun Bakım Ünitesi Sonuçlarına Etkisi

Abstract

Amaç: Bu çalışmada amacımız kritik koronavirüs hastalığı-2019 (COVID-19) hastalarında hepsidin düzeylerinin değişimi ve D vitamini düzeylerinin, enflamatuvar belirteçler, yoğun bakım ünitesi (YBÜ) yatış süresi ve yoğun bakım sonucu ile ilişkisinin değerlendirilmesi amaçlanmıştır.

Gereç ve Yöntem: 1 Mart 2021 ile 17 Mayıs 2021 arasında hastanemiz pandemi YBÜ’de yatışı yapılan yetişkin hastalar prospektif olarak çalışmaya dahil edildi. Hastaların 1, 2, 3 ve 7. gün hepsidin düzeyleri ve diğer enflamatuvar belirteçleri, kabul vitamin D düzeyleri, yoğun bakım yatış süreleri ve yoğun bakım sonuçları kaydedilerek incelendi.

Bulgular: Hastaların ortanca yaşı 60,5 (52,50-71,25) ve 20’si (%66,7) erkekti. Hepsidin ve lenfosit sayısının 1. günden 7. güne olan süre içerisinde anlamlı olarak yükseldiği gözlendi (p=0,01 ve p<0,01, sırasıyla). C-reaktif protein (CRP) ve prokalsitonin seviyelerinin ise 1. günden 7. güne olan süre içerisinde gerilediği gözlendi (p<0,01 ve p<0,01, sırasıyla). Hastaların YBÜ’ye kabulünde çalışılan hepsidin düzeyi ile enflamatuvar parametreler [IL-6 (p=0,61), CRP (p=0,82) ve ferritin (p=0,27)], D vitamini (p=0,13) ve demir düzeyi (p=0,90) arasında korelasyon saptanmadı. Hepsidin düzeyleri ile yoğun bakım mortalitesi arasında ilişki tespit edilemedi (p=0,95).

Sonuç: Bu çalışma ile kritik COVID-19 hastalarında hepsidin düzeylerinin normal sınırlar üzerinde seyrettiği tespit edilmiştir. Ancak bulgularımız, hepsidin, IL6, serum ferritin ve D vitamini düzeylerinin COVID-19 mortalite tahmininde kullanımını destekler nitelikte değildir.

Keywords

Yoğun Bakım , Hepsidin , Mortalite

Ethical Statement

Ankara Üniversitesi Tıp Fakültesi İnsan Araştırmaları Etik Kurulu’ndan 11.03.2021 tarihinde İ3-218-21 karar numarası ile onam alınmıştır.

Supporting Institution

-

Project Number

-

Thanks

-

References

• 1. Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. Bmj. 2020;368:m1036.
• 2. Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105:260.
• 3. Loreal O, Cavey T, Bardou-Jacquet E, et al. Iron, hepcidin, and the metal connection. Front Pharmacol. 2014;5.
• 4. Smith EM, Alvarez JA, Kearns MD, et al. High-dose vitamin D-3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults. Clin Nutr. 2017;36:980-5.
• 5. Rauf A, Shariati MA, Khalil AA, et al. Hepcidin, an overview of biochemical and clinical properties. Steroids. 2020;160:108661.
• 6. Bohn MK, Hall A, Sepiashvili L, et al. Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression. Physiology (Bethesda). 2020;35:288-301.
• 7. Edeas M, Saleh J, Peyssonnaux C. Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis? Int J Infect Dis. 2020;97:303-5.
• 8. Zhou C, Chen Y, Ji Y, et al. Increased Serum Levels of Hepcidin and Ferritin Are Associated with Severity of COVID-19. Med Sci Monit. 2020;26:e926178.
• 9. Sonnweber T, Boehm A, Sahanic S, et al. Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients’ performance: a prospective observational cohort study. Respir Res. 2020;21:276.
• 10. Hippchen T, Altamura S, Muckenthaler MU, et al. Hypoferremia is Associated With Increased Hospitalization and Oxygen Demand in COVID-19 Patients. Hemasphere. 2020;4:e492.
• 11. Delaye JB, Alarcan H, Vallet N, et al. Specific changes of erythroid regulators and hepcidin in patients infected by SARS-COV-2. J Investig Med. 2022;70:934-938.
• 12. Zhou C, Chen Y, Ji Y, et al. Increased serum levels of hepcidin and ferritin are associated with severity of COVID-19. Medical science monitor: international medical journal of experimental and clinical research. 2020;26:e926178-1.
• 13. Nai A, Lorè NI, Pagani A, et al. Hepcidin levels predict Covid-19 severity and mortality in a cohort of hospitalized Italian patients. American journal of hematology. 2021;96:E32-E5.
• 14. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis. 2020;95:304-7.
• 15. Henry BM, de Oliveira MHS, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58:1021-8.